Syndax to present new data on revumenib in leukemia
Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral ...
Syndax narrows FY24 CapEx view to $245M-$250M from $240M-$260M
Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ENDPOINTS NEWS13h
Syn­dax inks a $350M roy­al­ty deal; FDA push­es back de­ci­sion on Organon’s eczema drug
Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...
FiercePharma13h
Syndax inks $350M deal with Royalty Pharma for funding to launch 2 new drugs
To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...
Syndax agrees funding with Royalty Pharma for Niktimvo US sales
Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of ...